pid,mcid,nctid,criterion_text
26,1084,NCT03165227,UACR ≥ 200 and <3500 mg/g in spot urine (midstream urine sample) at Visit 1 measured by the central laboratory
26,1939,NCT03145298,Pulmonary capillary wedge pressure (PCWP) or LVEDP < 15 mm Hg
26,5111,NCT03078907,"<li>
<p>With the following hemodynamic characteristics assessed by right heart catheterization (RHC) prior to randomization:</p>
<ul>
<li>Mean pulmonary artery pressure (mPAP) ≥ 25 mmHg</li>
<li>Pulmonary vascular resistance (PVR) ≥ 240 dyn•sec/cm5 (or 3 Wood Units)</li>
<li>Pulmonary artery wedge pressure (PCWP) or left ventricular end-diastolic pressure (LVEDP) ≤ 15 mmHg.</li>
</ul>
</li>"
26,5189,NCT03078491,"End stage renal insufficiency (eGFR<30), or on dialysis (since impact of fluid shift on sensor lag not clearly understood)."
26,6163,NCT03059355,Impaired flow-mediated vasodilation (FMD <7%)
26,6887,NCT03044054,Patient's fibroadenoma size is greater or equal to 0.2 cc and less than 10 cc in volume (measured by ultrasound on the day of the procedure).
26,8915,NCT03005418,Preoperative imaging or clinical examination indicates the damaged vessel has a defect length of ≤ 38cm and is appropriately size matched to the 6mm Human Acellular Vessel (HAV) per the judgment of the treating surgeon taking into account vasoconstriction and situational inflow and outflow considerations.
26,10644,NCT02961114,Post-void residual urine volumes of > 350 cc
26,10929,NCT02953392,Residual bone height ranging from 6 to 9 mm.
26,11637,NCT02932410,"<p>Key Inclusion Criteria:</p><ul>
<li>Signed informed consent by the parent(s) or legally designated representative and assent from developmentally capable children prior to initiation of any study-mandated procedure</li>
<li>Males or females between greater than or equal to (&gt;=) 1 month and less than (&lt;) 18 years of age</li>
<li>Participants with body weight &gt;= 3.5 kilograms (kg) at randomization</li>
<li>Pulmonary arterial hypertension (PAH) diagnosis confirmed by historical RHC (mPAP greater than or equal to [&gt;=] 25 millimeters of mercury [mmHg], and Pulmonary artery wedge pressure [PAWP] less than or equal to [&lt;=] 15 mmHg, and Pulmonary vascular resistance index [PVRi] greater than [&gt;] 3 WU × m2), where in the absence of pulmonary vein obstruction and/or significant lung disease PAWP can be replaced by Left atrium pressure [LAP] or Left ventricular end diastolic pressure [LVEDP] (in absence of mitral stenosis) assessed by heart catheterization</li>
<li>PAH belonging to the Nice 2013 Updated Classification Group 1 (including participants with Down Syndrome) and of following etiologies: idiopathic PAH; heritable PAH; PAH associated with congenital heart disease (CHD); Drug or toxin induced PAH; PAH associated with HIV; PAH associated with connective tissue diseases (PAH-aCTD); and World health organization (WHO) Functional class I to III</li>
<li>Females of childbearing potential must have a negative pregnancy test at Screening and at Baseline, and must agree to undertake monthly pregnancy tests, and to use a reliable method of contraception (if sexually active) up to the end of study (EOS)</li>
</ul>"
26,50920,NCT01508390,Prostate volume greater than 20 cc and less than 100 cc
26,14721,NCT02836899,Mean pulmonary artery pressure ≥ 40 mm Hg and PVR > 4 Wood Units.
26,16096,NCT02784535,"Neurogenic Orthostatic Hypotension (defined by a reduction of ≥20 mmHg drop in SBP within 3 minutes of standing, associated with impaired autonomic reflexes as assessed by autonomic function tests."
26,18213,NCT02707692,Documented CD4 count at enrollment (>250 cells/µl)
26,19015,NCT02675959,Tricuspid Regurgitant Jet Velocity (TRV) > 3.0 m/s
26,19622,NCT02652247,"Conditions limiting the subject's ability to tolerate collection of lavage specimens, including: FIO2 > 80%; PEEP > 16 cmH2O; Intracranial pressure >20 cmH2O; Tracheal or mucosal bleeding; Platelet count < 20,000 cells/uL; INR > 2.0"
26,20927,NCT02598713,High PEEP requirement at enrollment (PEEP higher than 8 cmH2O)
26,21277,NCT02592473,"IPSS score at initial evaluation should be greater than 7, and uroflowmetry (Qmax) of <12mL/s (milliliters per second) ."
26,21784,NCT02583360,Room air or supplemental oxygen of ≤1liter/minute (LPM)
26,23424,NCT02554903,Doppler mean blood pressure < 65 mmHg at Randomization.
26,23474,NCT02554786,A one-time repeat/re-testing of percent predicted FEV1 (prebronchodilator FEV1) is allowed at Visit 101 and at Visit 102.
26,23861,NCT02546583,Cumulative 6-hour sodium output < 100 mmol following Visit 1 IV loop diuretic dose
26,24876,NCT02525861,The participant is experiencing or has a history of chronic severe cor pulmonale (resting mean pulmonary artery pressure > or =40 millimeters) of mercury [mm Hg]).
26,26028,NCT02508311,Males with maximal inspiratory pressure (MIP) < 90 cmH2O or
26,27230,NCT02489019,Patients with a pre-induction mean arterial blood pressure (MAP) less than 50 or greater than 150
26,28099,NCT02473354,"has a COHb greater than 3%, or MetHb greater than 2% [measured by venous blood sample co-oximetry];"
26,28379,NCT02468778,Cardiogenic shock (SBP <90 mmHg for >1 hour with either cool clammy skin OR oliguria OR altered sensorium AND cardiac index <2.2 L/min/m^2)
26,28791,NCT02464696,Partial pressure of arterial oxygen (PaO2):fraction of inspired oxygen (FiO2) ratio =< 300 mmHg OR a peripheral capillary oxygen saturation (SaO2):FiO2 =< 357
26,28803,NCT02464696,pH < 7.30 or partial pressure of carbon dioxide (pCO2) > 50 (if available)
26,30933,NCT02414269,Baseline pulse oximetry is less than 92% on Room air
26,32773,NCT02370095,Acute onset need for 4 liters per minute (LPM) or more of supplemental oxygen to maintain Arterial partial pressure of oxygen (PaO2) > 60 mmHg or arterial O2 saturation > 90% by pulse oximetry.
26,33700,NCT02349867,Persistent heart rate (HR) < 50 or > 120 beats per minute (bpm).
26,36648,NCT02272049,Baseline oximetry at MRI visit of less than 95% on room air or less than 95% on a previously prescribed dosage of oxygen delivered by nasal cannula
26,39609,NCT02169089,GFR <90 and evidence of proteinuria (Urine albumin/creatinine ratio of >30 mg/g or equivalent) in a urine specimen within 12 months OR GFR <60 mg/g regardless of proteinuria.
26,39702,NCT02167009,Patient has a peak urine flow rate < 12 mL/sec
26,41372,NCT02122328,Recipient twin with a middle cerebral artery peak systolic velocity > 1.5 multiples of the median (indicative of fetal anemia).
26,50187,NCT01589263,Voided volume greater than 125 ml
26,44336,NCT02000115,Subject has senile degenerative aortic valve stenosis with echocardiographically derived criteria: mean gradient >40 mmHg or jet velocity greater than 4.0 m/s or Doppler Velocity Index <0.25 and an initial aortic valve area (AVA) of ≤ 1.0 cm2 (indexed effective orifice area (EOA) ≤ 0.6 cm2/m2). (Qualifying AVA baseline measurement must be within 60 days prior to informed consent).
26,45751,NCT01937884,"Exhibits Acute Hypoxemic Respiratory Failure as defined as: PaO2/FiO2 ≤ 300 or SpO2/FiO2 ≤ 260, No evidence of cardiac dysfunction, Mechanically ventilated,"
26,47576,NCT01817751,Persistent heart rate (HR) <50 or >120 beats per minute (bpm)
26,49093,NCT01686659,At least one finger available and accessible for performing non-invasive hemoglobin monitoring (preoperative perfusion index greater than 0.5)
26,54648,NCT02133872,More than one episode(s) of orthostatic hypotension (reduction of SBP of ≥ 20mmHg of diastolic blood pressure (DBP) of ≥ 10mmHg within 3 minutes of standing).
26,50984,NCT01504373,Peak inspiratory pressure (PIP) > 30 cmH2O
26,52914,NCT00985205,"<li>
<p>a) Patients without known renal disease and renal dysfunction defined as a serum creatinine &gt;171 µmol/L or a urine output of less than 500 mL/last 24 hours (or 80 mL/last 4 hours if a 24 hour period of observation is not available).</p>
<p>b) Patients with acute on chronic renal failure (pre-dialysis) with an absolute increase of &gt;80 µmol/L from baseline or pre-admission creatinine or a urine output of &lt;500 mL/last 24 hours (or 80 mL/last 4 hours).</p>
<p>c) Patients with chronic renal failure on dialysis will be excluded.</p>
</li>"
26,53677,NCT00719888,Diffusion capacity for carbon monoxide corrected (DLCOcorr) > 50% normal or a pediatric patient who is unable to perform pulmonary function tests (PFTs) but has adequate pulmonary function
26,54285,NCT00338377,Pulmonary function tests (FEV1>65% or FVC>65%of predicted) within 6 months of lymphodepletion. (Turnstile II - Chemotherapy/Cell Infusion - Inclusion Criteria).
26,9998,NCT02981082,Right heart catheterization demonstrating mPAP≥ 25 mmHg and PCWP or left ventricular end diastolic pressure ≤15mm Hg and pulmonary vascular resistance ≥240 dynes/cm-5 (3 Wood units) within 12 weeks prior to study entry.
26,758,NCT03171168,Patients with a Visual Analog Scale (VAS) pain score of ≥3cm (measured at baseline).
26,3375,NCT03114020,"Subjects with measured DLCO of ≤ 35%, or unable to perform a reproducible DLCO"
26,30231,NCT02430077,Hematocrit of less than 30%.
